Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sarat Chandarlapaty discloses the following relationships and financial interests:
-
AstraZeneca
Professional Services and Activities -
Blueprint Medicines
Professional Services and Activities -
Casdin Capital, LLC
Professional Services and Activities -
Daiichi Sankyo
Professional Services and Activities -
eFFECTOR Therapeutics
Equity; Professional Services and Activities -
Eli Lilly and Company
Professional Services and Activities (Uncompensated) -
Encore Medical Education
Professional Services and Activities -
Genesis Therapeutics
Professional Services and Activities
-
Gerson Lehrman Group
Professional Services and Activities -
Novartis
Professional Services and Activities -
Nuvalent, Inc.
Professional Services and Activities -
Odyssey Biosciences
Equity; Fiduciary Role / Position; Intellectual Property Rights -
Prelude Therapeutics
Professional Services and Activities -
SAGA Diagnostics
Professional Services and Activities -
Springer Nature Limited
Professional Services and Activities -
Totus Medicines Inc.
Equity
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures